Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

PURPOSE: Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured by activating peripheral blood mononuclear cells, including antigen presenting cells (APCs), with a fusion protein containing prostatic acid phosphatase. Analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheikh, Nadeem A., Petrylak, Daniel, Kantoff, Philip W., dela Rosa, Corazon, Stewart, Frances P., Kuan, Ling-Yu, Whitmore, James B., Trager, James B., Poehlein, Christian H., Frohlich, Mark W., Urdal, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541926/
https://www.ncbi.nlm.nih.gov/pubmed/22865266
http://dx.doi.org/10.1007/s00262-012-1317-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541926/
https://www.ncbi.nlm.nih.gov/pubmed/22865266
http://dx.doi.org/10.1007/s00262-012-1317-2

Ejemplares similares